Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 6/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14635584 | 1.00 | SLC6A3 (0.55) | SLC6A3KCNH2SCN3ASLC6A2SLC6A4 | |
| SCHEMBL840272 | 0.91 | KCNH2 (0.54) | SLC6A3KCNH2SCN3ASLC6A2SLC6A4 | |
| SCHEMBL2040685 | 0.91 | KCNH2 (0.54) | SLC6A3KCNH2SCN3ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL840271 | 0.90 | KCNH2 (0.52) | SLC6A3KCNH2SCN3ASLC6A2SLC6A4 | |
| SCHEMBL14635593 | 0.88 | KCNH2 (0.52) | SLC6A3KCNH2SCN3ASLC6A2SLC6A4 | |
| SCHEMBL14635594 | 0.88 | KCNH2 (0.52) | SLC6A3KCNH2SCN3ASLC6A2SLC6A4 | |
| SCHEMBL24491224 | 0.84 | KCNH2 (0.46) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL8698718 | 0.84 | SLC6A3 (0.49) | SLC6A3KCNH2SCN3ASLC6A2SLC6A4 | |
| SCHEMBL8698715 | 0.84 | SLC6A3 (0.49) | SLC6A3KCNH2SCN3ASLC6A2SLC6A4 | |
| SCHEMBL12973321 | 0.82 | KCNH2 (0.45) | SLC6A3KCNH2SCN3ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| EP-3610872-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2019-10-03 | — | — | US | disclosed |
| EP-3074008-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATION | EPICS THERAPEUTICS (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2019-07-23 | — | — | US | disclosed |
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2018-10-18 | — | — | US | disclosed |
| US-10017468-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | OGEDA SA (BE) | 2018-07-10 | — | — | US | disclosed |
| US-20170283376-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2017-10-05 | — | — | US | disclosed |
| EP-2513053-B1 | Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders | OGEDA SA (BE) | 2017-10-04 | — | — | EP | disclosed |
| US-9770435-B2 | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | OGEDA SA (BE) | 2017-09-26 | — | — | US | disclosed |
| US-9695120-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | OGEDA SA (BE) | 2017-07-04 | — | — | US | disclosed |
| US-20160303075-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2016-10-20 | — | — | US | disclosed |
| EP-3074008-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | Euroscreen S.A. (BE) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015078949-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN SA (BE) | 2015-06-04 | — | — | WO | disclosed |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | SLC6A3 1083/4885KCNH2 2405/4885SCN3A 1465/4885 |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | SLC6A3 1083/4885KCNH2 2405/4885SCN3A 1465/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | SLC6A3 1083/4885KCNH2 2405/4885SCN3A 1465/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | SLC6A3 1806/4885KCNH2 3613/4885SCN3A 2658/4885 |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GIPR, GPR88, GPR119 | SLC6A3 1271/4885KCNH2 1908/4885SCN3A 1888/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | SLC6A3 1083/4885KCNH2 2405/4885SCN3A 1465/4885 |
| US-10017468-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GIPR, GPR88, FFAR3 | SLC6A3 1076/4885KCNH2 1991/4885SCN3A 1724/4885 |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | SLC6A3 1806/4885KCNH2 3613/4885SCN3A 2658/4885 |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | SLC6A3 1221/4885KCNH2 2051/4885SCN3A 1653/4885 |
| US-20160303075-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | PTGS1, PTGES, PTGER1 | SLC6A3 4509/4885KCNH2 3364/4885SCN3A 2371/4885 |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | SLC6A3 1211/4885KCNH2 2421/4885SCN3A 1512/4885 |
| US-20170283376-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | SLC6A3 1083/4885KCNH2 2405/4885SCN3A 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.